Abstract
Purpose::
To evaluate the efficacy of topical nepafenac 0.1% in the treatment of diabetic cystoid macular edema.
Methods::
A retrospective chart review was conducted to evaluate patients with fovea involving cystoid macular edema treated with twice daily topical nepafenac . Patients were excluded if they had focal laser, intravitreal triamcinolone acetonide, intravitreal VEGF therapy, or periocular steroids within 4 months of initiating nepafenac. Any patient a history of cataract extraction within the past year was excluded. No patient received any concomitant therapy for macular edema . Visual acuity was measured using an ETDRS chart and retinal thickness was measured with a Stratus 3 OCT. Patients were evaluated for adverse effects and a paired-t test was used to compare foveal thickness and visual acuity of the two groups.
Results::
Six eyes from 5 patients were identified. The mean age was 67.9 years (Range 59-76) and all the patients had type 2 diabetes mellitus for at least 10 years. The mean foveal thickness pre-treatment was 383.5 microns (range 286-517), and the mean visual acuity was 0.86 logMAR (range 0.3-1.3). The mean time of treatment was 4.4 months (range 3-8). The mean foveal thickness at the final visit was 254.3 microns (range 215-310). This was a statistically significant difference (P= 0.008). No patients experienced an increase in retinal edema measured by OCT nor a decrease in visual acuity. There was no change in mean visual acuity at the final visit (0.86 logMAR). No adverse events were reported.
Conclusions::
. This small retrospective study demonstrated the efficacy of topical nepafenac to reduce OCT measured foveal thickness in diabetic cystoid macular edema. Nepafenac may be useful in the treatment of diabetic cystoid macular edema.
Keywords: diabetic retinopathy • macula/fovea • edema